QuatRx Reports Positive Phase 3 Results For Ophena
QuatRx has reported the positive top-line efficacy results from the first of two patient cohorts in its second pivotal phase 3 trial of the investigational compound, Ophena (ospemifene
Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD).